opentargets-database

You can identify drug targets by querying target-disease associations through the Open Targets Platform. This process retrieves genetic, omics, and clinical evidence to help prioritize therapeutic targets based on tractability and safety profiles for specific diseases.

Assessing target druggability and safety involves querying comprehensive biomedical data for target-disease links. You can evaluate a gene's genetic evidence, tractability, and safety profiles systematically to determine its therapeutic potential and suitability for drug development.

Yes, you can retrieve detailed clinical, genetic, and literature evidence for target-disease associations. The skill queries the Open Targets Platform to gather supporting evidence, facilitating a systematic analysis of therapeutic target identification and drug repurposing opportunities.

Finding existing drugs for new indications involves querying drug discovery data and target-disease associations. By examining the supporting evidence and chemical data for established targets, you can identify potential opportunities for drug repurposing across different diseases.

Yes, target identification works by querying the Open Targets Platform GraphQL API. It retrieves comprehensive biomedical data, including genetic, omics, and chemical evidence, to evaluate target druggability, safety, and therapeutic potential for drug discovery.

You should avoid systematic target-disease association queries when you lack specific disease or target identifiers. It is also unsuitable if your research requires real-time clinical trial monitoring rather than aggregated genetic, omics, and literature evidence for target prioritization.